衡量2020-21年全球抗微生物药物耐药性应对:114个国家的系统性治理分析
该研究系统审查了114个国家抗微生物药物耐药性国家行动计划的内容,应用包含18个领域和54个指标的治理框架进行评分。2020-2021年间全球平均治理得分为51分(SD 14),挪威最高(85分),密克罗尼西亚联邦最低(28分)。参与领域得分最高(83分),问责和反馈机制领域得分最低(均为30分),监测与评估得分较低(38分)。
要点
- 全球抗微生物药物耐药性治理平均得分为51分(SD 14),国家间差异显著。
- 参与领域得分最高(83分),问责和反馈机制领域最低(均为30分)。
- 监测与评估得分(38分)低于政策设计(55分)和实施工具(54分)。
核心结论
- 国际抗微生物药物耐药性控制努力在国家间差异显著。
- 监测与评估工作需改进以持续了解国家和国际进展。
- 国际应对可能与抗微生物药物耐药性的规模和严重性不相称。
研究设计与样本
- 系统性治理分析,系统审查114个国家抗微生物药物耐药性国家行动计划的内容。
- 应用包含18个领域和54个指标的治理框架,涵盖政策设计、实施工具、监测与评估三个整体领域。
- 三位研究者独立审查每个国家行动计划,采用Cochrane方案确保可靠性,通过共识解决评分分歧。
- 数据来源包括三方抗微生物药物耐药性国家自评调查、全球抗微生物药物耐药性和使用监测系统、全球抗微生物药物耐药性研发中心及WHO数据集。
主要发现
- 2020-2021年间,114个国家的平均抗微生物药物耐药性治理得分为51(SD 14)。
- 挪威治理得分最高(均值85 [SD 32]),密克罗尼西亚联邦得分最低(28 [37])。
- 得分最高的领域为参与(83 [16]),得分最低的领域为问责(30 [18])和反馈机制(30 [25])。
- 政策设计领域得分为55(13),实施工具领域得分为54(17),两者相近;监测与评估领域得分为38(20),较低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding strategic commitments and policy responses to overcome antimicrobial resistance at the national, regional, and global levels is required to evaluate current progress and direct future planning. National action plans (NAPs) are the primary mechanism for guiding national strategy and action for antimicrobial resistance governance. Although several NAPs have been developed, no comprehensive content analysis of these plans exists. Using a governance framework, we aimed to assess all publicly available NAPs on antimicrobial resistance. METHODS: We systematically reviewed the contents of NAPs on antimicrobial resistance from 114 countries, applying a governance framework containing 18 domains and 54 indicators in three integral areas: policy design, implementation tools, and monitoring and evaluation. As well as manually searching NAPs and doing online and literature searches that were relevant to specific indicators from repository inception to June 1, 2022, several data sources were used to generate scores, including the Tripartite Antimicrobial Resistance Country Self-Assessment Survey, the Global Antimicrobial Resistance and Use Surveillance System, the Global Antimicrobial Resistance Research and Development Hub, and various WHO datasets. NAPs were included if the country had also submitted the NAP to the Tripartite Antimicrobial Resistance Country Self-Assessment Survey 2020-21, if the NAP was retrievable through a publicly accessible database or website, and if the NAP was either published in English or eligible for machine translation. Three researchers independently reviewed each NAP and were initially blinded to the evaluations of other researchers. They generated a score using a quantification system for each of 54 indicators. The Cochrane protocol for ensuring reliability was followed. The three researchers were then unblinded and met to resolve any disagreements in scoring to reach a consensus agreement. In each case of discrepancy, consensus was reached between the researchers. We developed criteria to standardise the process of quantifying each indicator. We also weighted and collated relevant national data from various sources to generate composite scores concordant with the key governance areas. We transformed these data to a scale of 0 (worst) to 100 (best), ranked countries on the basis of their mean scores, and used descriptive statistics to analyse global and regional trends. FINDINGS: 306 NAPs were identified and 114 were eligible for analysis. Between 2020 and 2021, the mean antimicrobial resistance governance score was 51 (SD 14). Norway had the highest governance score (mean 85 [SD 32]), and the Federated States of Micronesia had the lowest governance score (28 [37]). The highest scoring domain was participation (83 [16]), and the lowest scoring domains were accountability (30 [18]) and feedback mechanism (30 [25]). Domains relating to policy design (55 [13]) and implementation tools (54 [17]) scored similarly, whereas monitoring and evaluation (38 [20]) efforts were lower. INTERPRETATION: International efforts to control antimicrobial resistance varied considerably between countries. Monitoring and evaluation efforts need improving for continuous understanding of national and international progress. International response might not be commensurate with the scale and severity of antimicrobial resistance. FUNDING: None.
引用
- Patel J, Harant A, Fernandes G, et al. Measuring the global response to antimicrobial resistance, 2020-21: a systematic governance analysis of 114 countries. Lancet Infect Dis. 2023. PMID: 36657475. doi:10.1016/S1473-3099(22)00796-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。